| Pathogenesis and clinical features of psoriasis CEM Griffiths, JNWN Barker The Lancet 370 (9583), 263-271, 2007 | 2656 | 2007 |
| Global epidemiology of psoriasis: a systematic review of incidence and prevalence R Parisi, DPM Symmons, CEM Griffiths, DM Ashcroft Journal of Investigative Dermatology 133 (2), 377-385, 2013 | 2400 | 2013 |
| Secukinumab in plaque psoriasis—results of two phase 3 trials RG Langley, BE Elewski, M Lebwohl, K Reich, CEM Griffiths, K Papp, ... New England Journal of Medicine 371 (4), 326-338, 2014 | 2212 | 2014 |
| Real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: an analysis of the APPRECIATE study TM Klein, C Blome, CE Kleyn, C Conrad, PG Sator, M Ståhle, K Eyerich, ... Dermatology and Therapy 12 (1), 81-95, 2022 | 1933 | 2022 |
| Psoriasis: epidemiology, clinical features, and quality of life RGB Langley, GG Krueger, CEM Griffiths Annals of the rheumatic diseases 64 (suppl 2), ii18-ii23, 2005 | 1441 | 2005 |
| Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial K Reich, FO Nestle, K Papp, JP Ortonne, R Evans, C Guzzo, S Li, ... The Lancet 366 (9494), 1367-1374, 2005 | 1316 | 2005 |
| Rook's textbook of dermatology T Burns, SM Breathnach, N Cox, C Griffiths John Wiley & Sons, 2008 | 1225 | 2008 |
| Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded … A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ... The Lancet 389 (10086), 2287-2303, 2017 | 1167 | 2017 |
| Definition of treatment goals for moderate to severe psoriasis: a European consensus U Mrowietz, K Kragballe, K Reich, P Spuls, CEM Griffiths, A Nast, J Franke, ... Archives of dermatological research 303, 1-10, 2011 | 1088 | 2011 |
| Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity LC Tsoi, SL Spain, J Knight, E Ellinghaus, PE Stuart, F Capon, J Ding, ... Nature genetics 44 (12), 1341-1348, 2012 | 1050 | 2012 |
| Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis CEM Griffiths, BE Strober, P Van De Kerkhof, V Ho, R Fidelus-Gort, ... New England Journal of Medicine 362 (2), 118-128, 2010 | 1032 | 2010 |
| Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 A Strange, F Capon, CCA Spencer, J Knight, ME Weale, MH Allen, ... Nature genetics 42 (11), 985, 2010 | 1017 | 2010 |
| European S3-guidelines on the systemic treatment of psoriasis vulgaris D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, ... Journal of the European Academy of Dermatology and Venereology 23 (SUPPL. 2 …, 2009 | 958 | 2009 |
| Keratinocytes as initiators of inflammation JNWN Barker, CEM Griffiths, BJ Nickoloff, RS Mitra, VM Dixit The Lancet 337 (8735), 211-214, 1991 | 958 | 1991 |
| Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence R Parisi, DP Symmons, CE Griffiths, DM Ashcroft J Invest Dermatol 133 (2), 377-385, 2013 | 882 | 2013 |
| Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe … A Blauvelt, KA Papp, CEM Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, ... Journal of the american academy of dermatology 76 (3), 405-417, 2017 | 871 | 2017 |
| Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials CEM Griffiths, K Reich, M Lebwohl, P Van De Kerkhof, C Paul, A Menter, ... The Lancet 386 (9993), 541-551, 2015 | 866 | 2015 |
| A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction KA Papp, S Tyring, M Lahfa, J Prinz, CEM Griffiths, AM Nakanishi, R Zitnik, ... British Journal of Dermatology 152 (6), 1304-1312, 2005 | 859 | 2005 |
| Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial TN Brooklyn, MGS Dunnill, A Shetty, JJ Bowden, JDL Williams, ... Gut 55 (4), 505-509, 2006 | 758 | 2006 |
| Rook's textbook of dermatology CEM Griffiths, J Barker, TO Bleiker, R Chalmers, D Creamer John Wiley & Sons, 2016 | 722* | 2016 |
